Abbvie Inc logo

ABBV - Abbvie Inc Share Price

$88 -1.3  -1.4%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £100.95bn
Enterprise Value £122.18bn
Revenue £25.14bn
Position in Universe 77th / 6413
Bullish
Bearish
Unlock ABBV Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ABBV Revenue Unlock ABBV Revenue

Net Income

ABBV Net Income Unlock ABBV Revenue

Normalised EPS

ABBV Normalised EPS Unlock ABBV Revenue

PE Ratio Range

ABBV PE Ratio Range Unlock ABBV Revenue

Dividend Yield Range

ABBV Dividend Yield Range Unlock ABBV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABBV EPS Forecasts Unlock ABBV Revenue
Profile Summary

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated April 10, 2012
Public Since January 2, 2013
No. of Shareholders: 48,516
No. of Employees: 30,000
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange New York Stock Exchange
Shares in Issue 1,478,867,665
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ABBV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ABBV
Upcoming Events for ABBV
Similar to ABBV
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.